Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WJKRI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DS-6157a
|
|||||
| Synonyms |
DS 6157a; DS6157a; DS-6157a
Click to Show/Hide
|
|||||
| Organization |
Daiichi Sankyo Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Gastrointestinal interstitial cancer [ICD11:2B5B]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
G-protein coupled receptor 20 (GPR20)
|
Antigen Info | ||||
| Payload Name |
DX-8951 derivative (DXd)
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) | 2.90% | High GPR20 expression (GPR20+++) | ||
| Patients Enrolled |
Histopathologically documented unresectable and/or metastatic gastrointestinal stromal tumor (GIST) following treatment with standard of care, including imatinib.
|
||||
| Administration Dosage |
1.6 mg/kg, 3.2 mg/kg, 4.8 mg/kg, 6.4 mg/kg, and 9.6 mg/kg intravenously on Day 1 of each 21-day cycle.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04276415 | Clinical Status | Phase 1 | ||
| Clinical Description | Phase 1, multicenter, open-label, first-in-human study of DS-6157a in subjects with advanced gastrointestinal stromal tumor. | ||||
| Primary Endpoint |
MTD=6.40 mg/kg.
|
||||
| Other Endpoint |
Median PFS=4.20 months (95% CI, 1.60-6.90), Objective response rate=2.86%, comprising 0 complete responses and 1 (2.86%) partial responses.
|
||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.